Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU

/PRNewswire/ -- Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium...

Related Keywords

Japan ,San Francisco ,California ,United States ,Japanese ,Luca Dezzani ,Obrian Kenney ,Kiran Patel ,Laboratory Abnormalities ,Exchange Commission ,York Heart Association ,Janssen Research Development ,Astex Pharmaceuticals ,Janssen Pharmaceuticals ,Clinical Development ,None Of Janssen Research Development ,Early Development ,Data Monitoring Committee ,European Medicines Agency ,Janssen Biotech Inc ,Johnson ,Janssen Scientific Affairs ,Vice President ,Solid Tumors ,Johnson Innovative ,Medical Affairs ,Bacillus Calmette Gu ,Breakthrough Therapy Designation ,Acute Myeloid Leukemia ,Fluid Retention ,Cardiovascular Adverse Reactions ,Torsades De Pointes ,New York Heart Association ,Independent Data Monitoring Committee ,Reversible Encephalopathy Syndrome ,Posterior Reversible Encephalopathy Syndrome ,Fetal Toxicity ,Prescribing Information ,Ischemic Cardiovascular Events ,Cutaneous Adverse Reactions ,All Grades ,Soft Tissue Mineralization ,Embryo Fetal Toxicity ,Innovative Medicine ,Janssen Research ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Participants With Advanced Solid Tumors ,Fibroblast Growth Factor Receptor ,Accessed May ,Johnson Amp ,